Drugs targeting blood vessels may be candidates for treating Alzheimer's

(Medical Xpress)—University of British Columbia researchers have successfully normalized the production of blood vessels in the brain of mice with Alzheimer's disease (AD) by immunizing them with amyloid beta, a protein widely associated with the disease.

While AD is typically characterized by a build-up of plaques in the brain, recent research by the UBC team showed a near doubling of blood vessels in the brain of mice and humans with AD.

The new study, published online last week in Scientific Reports, a Nature journal, shows a reduction of brain in mice immunized with amyloid beta – a phenomenon subsequently corroborated by human clinical data – as well as a reduction of plaque build-up.

"The discovery provides further evidence of the role that an overabundance of plays in AD, as well as the potential efficacy of amyloid beta as basis for an AD vaccine," says lead investigator Wilfred Jefferies, a professor in UBC's Michael Smith Laboratories.

"Now that we know is a factor in AD, if follows that drugs targeting blood vessels may be good candidates as an AD treatment."

AD accounts for two-thirds of all cases of . The number of Canadians living with dementia is expected to reach 1.4 million by 2013, according to the Alzheimer's Society of Canada.


Explore further

Researchers find a new culprit in Alzheimer's disease: Too many blood vessels

More information: www.nature.com/srep/2013/13022 … /full/srep01354.html
Journal information: Scientific Reports , Nature

Citation: Drugs targeting blood vessels may be candidates for treating Alzheimer's (2013, March 7) retrieved 22 August 2019 from https://medicalxpress.com/news/2013-03-drugs-blood-vessels-candidates-alzheimer.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more